Llwytho...
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Gynecol Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/ https://ncbi.nlm.nih.gov/pubmed/25602714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|